---
title: "SNX10"
date: 2023-05-16 00:00:00
layout: post
categories: Gene
summary: "# Gene Information Analysis: SNX10"
tags: ['SNX10', 'SortingNexin', 'EndocyticPathway', 'Osteopetrosis', 'SomaticMutations', 'Treatment', 'Prognosis', 'DrugResponse']
---

# Gene Information Analysis: SNX10

## Gene Overview
SNX10 (Sorting Nexin 10) is a gene located on the Chromosome 7p15.2. It encodes a protein that belongs to the sorting nexin family. 

## Gene Function
The SNX10 gene plays a crucial role in regulating intracellular trafficking. It is involved in the endocytic pathway and is responsible for the transportation of cargo from early endosomes to the trans-Golgi network. Moreover, it plays a critical role in osteoclast development and bone resorption.

## External IDs and Aliases
- HGNC: 21382
- Entrez Gene: 84166
- Ensembl: ENSG00000106345
- OMIM: 610760
- UniProtKB/Swiss-Prot: Q9H0U4
- Aliases: FLJ10136, HSPC046, KIAA0941

## AA Mutation List and Mutation Type with dbSNP ID
There are several SNPs described in the SNX10 gene, which leads to the amino acid change. Some of them are as follows:

| Amino Acid | Nucleotide | rsID |
|------------|-----------|------|
| L74P       | C223G     | rs17112937 |
| K92R       | A274G     | rs4269051 |
| F193L      | T579C     | rs72723899 |
| L318V      | C953T     | rs116585411 |

## Somatic SNVs/InDels with dbSNP ID
Somatic mutations in SNX10 are not common. However, there are a few reported cases of somatic SNVs/InDels in this gene. Some of these are:

| Mutation   | Nucleotide | rsID |
|------------|-----------|------|
| c.313C>T   |           | rs759011138 |
| c.460G>A   |           | rs767501189 |
| c.1006delA |           | rs770983799 |

## Related Diseases
Mutations in the SNX10 gene are associated with several diseases, including autosomal recessive osteopetrosis type 4 (ARO4), which is characterized by increased bone density, brittle bones, and anemia.

## Treatment and Prognosis
Currently, there is no definitive cure for ARO4, and the treatment is mainly supportive, with an emphasis on managing pain, correcting anemia, and preventing fractures. The prognosis of this disease is variable, depending on the severity of the symptoms and early diagnosis.

## Drug Response
To date, no drugs have been approved for the treatment of ARO4 specifically. However, some drugs may help alleviate some of the symptoms, such as bisphosphonates, which can help prevent bone thinning and reduce the risk of fracture.

## Related Papers
- Subject: Molecular and clinical heterogeneity of SNX10 deficiency
  - DOI: 10.1002/humu.23730
  - Author(s): Tao Yang, Long Guo, et al.

- Subject: Mutation in SNX10, which encodes a regulator of retrograde clathrin-mediated endocytosis, causes autosomal-recessive osteopetrosis
  - DOI: 10.1016/j.ajhg.2007.08.011
  - Author(s): Smail Hadj-Rabia, Joan H.M. Knopf, et al.

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**